Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-10-19
2010-10-05
Chong, Yong S (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253030, C514S252100
Reexamination Certificate
active
07807680
ABSTRACT:
A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
REFERENCES:
patent: 4352811 (1982-10-01), Strupczewski et al.
patent: 4462996 (1984-07-01), Noda et al.
patent: 4734416 (1988-03-01), Banno et al.
patent: 4804663 (1989-02-01), Kennis et al.
patent: 5006528 (1991-04-01), Oshiro et al.
patent: 5314506 (1994-05-01), Midler et al.
patent: 5360616 (1994-11-01), Flores et al.
patent: 5612346 (1997-03-01), Mesens et al.
patent: 5688801 (1997-11-01), Mesens et al.
patent: 5955422 (1999-09-01), Lin
patent: 6165442 (2000-12-01), Swaerd-Nordmo et al.
patent: 6267989 (2001-07-01), Liversidge et al.
patent: 6297231 (2001-10-01), Almarsson et al.
patent: 6455526 (2002-09-01), Kohn et al.
patent: 6482518 (2002-11-01), Short et al.
patent: 6495164 (2002-12-01), Ramstack et al.
patent: 6544526 (2003-04-01), Crabb et al.
patent: 6559128 (2003-05-01), Hamm et al.
patent: 6669963 (2003-12-01), Kampinga
patent: 6977257 (2005-12-01), Parab et al.
patent: 6987111 (2006-01-01), Greco et al.
patent: 7514072 (2009-04-01), Ehrenreich et al.
patent: 7541021 (2009-06-01), Sambuco et al.
patent: 2005/0032811 (2005-02-01), Brown
patent: 2009/0274628 (2009-11-01), Ottoboni et al.
patent: 0 072 662 (1982-08-01), None
patent: 0 941 066 (1999-09-01), None
patent: 1 407 785 (2004-04-01), None
patent: 1675573 (2008-10-01), None
patent: 2084594 (1996-05-01), None
patent: 2-191256 (1990-07-01), None
patent: 2003212852 (2003-07-01), None
patent: 2 082 401 (1997-06-01), None
patent: 2 104 692 (1998-02-01), None
patent: 2 169 574 (2001-06-01), None
patent: 92/10175 (1992-06-01), None
patent: WO 95/13814 (1995-05-01), None
patent: 95/33488 (1995-12-01), None
patent: WO 99/12549 (1999-03-01), None
patent: 00-35475 (2000-06-01), None
patent: 01/58428 (2001-08-01), None
patent: WO 01/72297 (2001-10-01), None
patent: WO 03/026659 (2002-09-01), None
patent: WO 02/085366 (2002-10-01), None
patent: 03/024426 (2003-03-01), None
patent: WO 03/026659 (2003-04-01), None
patent: WO 2004/006886 (2004-01-01), None
patent: WO 2004/017897 (2004-03-01), None
patent: WO 2004/064752 (2004-08-01), None
patent: WO 2005/016262 (2005-02-01), None
Pharmaceutical Dosage Forms: Disperse Systems, vol. 1, pp. 153-163 (1998), Lieberman et al. eds., Marcel Dekker Inc.
Remington's Pharmaceutical Sciences, pp. 591-592 (1990), Gennaro et al. eds., Mack Publishing Co.
Handbook of Pharmaceutical Excipients(Second Edition), pp. 78-81 (1994), Wade and Waller eds., American Pharmaceutical Association.
Pharmaceutical Dosage Forms: Disperse Systems, vol. 2, pp. 261-301 (1996), Lieberman et al. eds., Marcel Dekker Inc.
Handbook of Pharmaceutical Excipients, pp. 45-48 (1986), American Pharmaceutical Association.
Nema et al,PDA J. of Pharm. Sci.&Tech., 51(4):166-171 (1997).
Edman.,J. of Aerosol Medicine, 7:S-3 to S-6 (1994).
Altamura et al.,Drugs, 63(5):493-512'(2003).
Zuidema et al.,International J. of Pharm., 47:1-12 (1988).
Strickley et al,PDA J. of Pharm. Sci.&Tech., 53(6):324-349 (1999).
Akers et al,J. or Parenteral Science&Technology, 41(3):88-96 (1987).
Handbook of Pharmaceutical Excipients, American Pharmaceutical Association et al., publs., pp. v-vi (table of contents) (1986).
Garza-Flores et al.,Contraception, 37(5):471-481 (1988).
Garza-Flores et al.,Contraception, 30(4):371-379 (1984).
Diaz-Sánchez et al.,Contraception, 35(1):57-68 (1987).
Nakagawa, Kazuyuki et al., Derivatives of 3, 4-dihydrocarbostyril as beta-adrenergic blocking agents, J. Med. Chem.; 1974; 17(5) pp. 529-533.
Petigara, R. B. et al., Synthesis and central nervous system depressant activity of new piperazine derivatives, 1, J. Med. Chem, 1968; 11(2) pp. 332-336.
Fielden, Marvel L, et al., Synthesis and central nervous system depressant activity of some 5-(2-substituted alkyl)-2-oxazolidinones, J. Med. Chem.; 1973; 16(10) pp. 1124-1128.
The Pharmacological Basis of Therapeutics (Goodman and Gilam, Ed., 1975); pp. 47-53, 153-197 and 590-623.
Alfonso R. Gennaro, ed., “Remington: The Science and Practice of Pharmacy”, 19thEdition, Mack Publishing Company 1995, pp. 1668-1671.
European Pharmcopeia 6thEdition, published Jul. 16, 2007, p. 736.
Prescribing information for Abilify® (Aripiprazole).
Srinivas K.S., Buchireddy R., Madhusudhan G., Mukkanti K., Srinivasulu P., “Stress Degradation Studies on Aripiprazole and Development of a Validated Stability Indicating LC Method”, Chromatographia, vol. 68, pp. 635-640 (2008).
Prescribing information for Kenalog®-10 Injection—triamcinolone acetonide injectable suspension, USP.
Prescribing information for Depo-Provera® Contraceptive Injection—medroxyprogesterone acetate sterile aqueous suspension, 150 mg/mL, USP.
Nakamura, A. and Okada, R., “The coagulation of particles in suspension by freezing-thawing—I. Effect of freezing-thawing conditions and other factors on coagulation”, Colloid & Polymer Sci., vol. 254, pp. 718-725 (1976).
Nakamura, A. and Okada, R., “The coagulation of particles in suspension by freezing-thawing—IV. Prevention of coagulation by network or eutectic formation”, Colloid & Polymer Sci., vol. 255, pp. 362-367 (1977).
Clausi A.L., Merkley S.A., Carpenter J.F., Randolph T.W., “Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying”, Journal of Pharmaceutical Science, vol. 97, No. 6, pp. 2049-2061 (2008).
Heller, M.C., Carpenter, J.F. and Randolph, T.W., “Protein formulation and lyophilization cycle design: Prevention of damage due to freeze-concentration induced phase separation,” Biotechnology & Bioengineering vol. 63, No. 2, pp. 166-174 (1999).
Franks F., “Freeze-drying of bioproducts: putting principles into practice”, European Journal of Pharmaceutics and Biopharmaceutics, vol. 45, pp. 221-229 (1998).
Zapata, M.I., Peck, G.E., Hem, S.L., White, J.L., and Feldkamp, J.R., “Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels”, Journal of Pharmaceutical Science, vol. 73, No. 1, pp. 3-8 (1984).
Nakamura, A. and Okada, R., “The coagulation of particles in suspension by freezing-thawing—II. Mechanism of coagulation”, Colloid & Polymer Science, vol. 254, pp. 497-506 (1976).
Tsapis, N., Dufresne, E.R., Sinha, S.S., Riera, C.S., Hutchinson, J.W., Mahadevan, L., and Weitz, D.A., “Onset of Buckling in Drying Droplets of Colloidal Suspensions”, Physics Review Letters, vol. 94, pp. 018302-1 to 018302-4 (2005).
Maa Y.F., Zhao L., Payne L.G., Chen D., “Stabilization of alum-adjuvanted vaccine dry powder formulations: Mechanism and application”, Journal of Pharmaceutical Science, vol. 92, pp. 319-332 (2003).
Hirakura Y., Kojima S., Okada A., Yokohama S., Yokota S., “The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11)”, International Journal of Pharmaceutics, vol. 286, Nos. 1-2, pp. 53-67 (2004).
Nakamura, A. and Okada, R., “The coagulation of particles in suspension by freezing-thawing—III. Prevention of coagulation by unfrozen water”, Colloid & Polymer Science, vol. 255, pp. 343-356 (1977).
Clausi, A. et al, “Influence of Protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvants in a model alkaline phosphatase vaccine,” Journal Pharmaceutical Sciences, vol. 98, pp. 114-121 (2009).
Clausi, A. et al, “Influence of Particle Size and antig
Kostanski Janusz W.
Matsuda Takakuni
Naringrekar Vijay H.
Nerurkar Manoj
Chong Yong S
Otsuka Pharmaceutical Co. Ltd.
Sughrue & Mion, PLLC
LandOfFree
Controlled release sterile injectable aripiprazole... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release sterile injectable aripiprazole..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release sterile injectable aripiprazole... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4224589